Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Dazukibart in Healthy Japanese Adults
NCT05037409Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dazukibart in dermatomyositis (DM) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Infusion Related Reaction (IRR) and 2 more. Started Sep 2021; status: completed.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05037409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037409.